How long you can live with untreated prostate cancer depends almost entirely on the grade and stage of the cancer at diagnosis. For low and intermediate-risk prostate cancer that hasn’t spread beyond the prostate, the 15-year survival rate is about 97%, even without surgery or radiation. For aggressive or advanced disease, the picture is very different.
This wide range is what makes prostate cancer unusual. Some men live decades without treatment and die of something else entirely. Others have a fast-growing form that needs immediate intervention. Understanding where your cancer falls on that spectrum is the most important factor.
Low-Risk Prostate Cancer: Decades of Survival
The strongest evidence on untreated prostate cancer comes from the ProtecT trial, a landmark study that followed men with localized prostate cancer for 15 years. Men were randomly assigned to either active surveillance (monitoring without treatment), surgery, or radiation therapy. At the 15-year mark, 97% of men were still alive regardless of which group they were in. Put simply, whether men had their prostate removed, received radiation, or did nothing but monitor the cancer, their survival was the same.
This is why the American Urological Association now recommends active surveillance as the preferred approach for low-risk prostate cancer, not just an acceptable alternative. The guidelines have even merged the old “very low-risk” and “low-risk” categories together, since the recommended management is the same for both: watch and wait.
About 80% of men on active surveillance in the ProtecT trial stayed on that path for the full study period without ever needing treatment. Roughly 10% saw their disease spread, either locally around the prostate or to distant sites. But men who received treatment within the first 12 months of diagnosis cut that spread risk in half, down to about 5%. This means active surveillance works partly because it catches the cancers that do progress early enough to treat them effectively.
What Makes Some Prostate Cancers Dangerous
Not all prostate cancers behave the same way. The Gleason score (or Grade Group, its newer equivalent) is the single best predictor of how a prostate cancer will behave over time. Low-grade cancers, those with a Gleason score of 6 or a Grade Group of 1, grow so slowly that many experts have argued they shouldn’t even be called cancer. These are the cancers where 15-year survival sits at 97% without treatment.
Higher-grade cancers (Gleason 8 to 10, or Grade Groups 4 and 5) are a fundamentally different disease. They grow faster, spread earlier, and carry a much higher risk of death if left untreated. For these cancers, the question isn’t whether to treat but how aggressively.
One useful marker for tracking how fast a prostate cancer is growing is how quickly the PSA level doubles. Research on untreated men found that a PSA doubling time shorter than 12 months signals serious danger. When baseline PSA was elevated, men with a doubling time under 12 months had roughly 7.5 times the risk of dying from prostate cancer compared to men whose PSA doubled more slowly. Even a doubling time under 10 years (120 months) consistently correlated with disease progression on biopsy and the presence of clinically significant cancer. About 27% of untreated men in one study had rapid doubling times under four years.
Metastatic Prostate Cancer Without Treatment
Once prostate cancer has spread to bones, lymph nodes, or other organs, the survival timeline shortens considerably. Untreated metastatic prostate cancer typically progresses within a few years. The median survival for men with distant metastases, even with treatment, is roughly five years, though this varies widely based on the volume and location of the spread.
Without any form of hormone therapy or other systemic treatment, metastatic prostate cancer progresses faster. Prostate cancer cells rely heavily on testosterone to grow, and blocking that hormone is the cornerstone of treatment for advanced disease. Men who forgo this treatment allow the cancer to grow unchecked, which can accelerate bone pain, fractures, spinal compression, and organ damage.
Age and Competing Health Risks
Prostate cancer is most commonly diagnosed in men over 65. At that age, heart disease, stroke, diabetes, and other conditions are often more immediate threats than a slow-growing prostate tumor. Many men with low-grade prostate cancer will die with the disease rather than from it. This is a core reason why active surveillance works so well for older men with low-risk disease: the cancer simply doesn’t have time to become lethal before something else does.
For a 65-year-old man diagnosed with low-grade localized prostate cancer, the realistic answer to “how long can I live without treatment” is often “as long as you would have lived anyway.” His risk of dying from prostate cancer over the next 15 years is around 3%, while his risk of dying from cardiovascular disease, other cancers, or other age-related causes is far higher.
For a younger man, say in his 50s, the calculus shifts. He has more years ahead for a slow-growing cancer to eventually progress. Active surveillance is still appropriate, but monitoring becomes more important because there’s a longer window for the disease to change character.
What “Untreated” Actually Means in Practice
It’s worth clarifying that in modern medicine, truly untreated prostate cancer is rare. What most men experience when they skip surgery or radiation is active surveillance: regular PSA blood tests, periodic biopsies, and sometimes imaging scans. This isn’t the same as ignoring the cancer. It’s a structured monitoring program designed to catch any changes early enough to intervene if needed.
The ProtecT trial results apply to men who were being monitored, not men who received a diagnosis and never saw a doctor again. A man who is diagnosed, declines all follow-up, and never has his PSA checked again is in a different situation. Without monitoring, a cancer that shifts from low-grade to aggressive could go unnoticed until it has already spread.
The practical takeaway: if you have low or intermediate-risk localized prostate cancer, skipping surgery and radiation is a well-supported choice backed by 15 years of high-quality data. But that choice works best when paired with regular monitoring so that the small percentage of cancers that do become dangerous get caught in time.